CYR61和VEGF-C表达水平与良性前列腺增生临床进展的相关性分析

马丁; 任瑞民; 尚吉文; 程伟; 张雁钢

doi:10.13201/j.issn.1001-1420.2019.06.008

CYR61和VEGF-C表达水平与良性前列腺增生临床进展的相关性分析

- 山西医学科学院山西大医院泌尿外科(太原, 030031)

详细信息

通讯作者: 张雁钢,E-mail:urozyg@163.com

中图分类号: R697.32

收稿日期: 2018-03-25

Correlation study between BPH clinical progression and the expression of CYR61 and VEGF-C

- Department of Urology, Shanxi Dayi Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030031, China

More Information

Corresponding author: ZHANG Yangang, E-mail: urozyg@163.com

Received Date: 25 March 2018

摘要

摘要: 目的:良性前列腺增生(BPH)是一种临床进展性疾病,本研究观察了富半胱氨酸61(CYR61)、血管内皮生长因子-C (VEGF-C)、IL-6、细胞色素C (cytochrome c)、凋亡蛋白caspase-3及细胞核增殖指数Ki-67在BPH组织中的表达,并分析与BPH临床进展危险因素之间的相关性,探讨预测BPH临床进展的分子标志物。方法:收集BPH患者前列腺标本288例,记录所有患者的年龄、前列腺体积、血清PSA水平及国际前列腺症状评分(IPSS)。明确前列腺组织中BPH病理学改变后将所有标本制作为BPH组织芯片。采用免疫组化ABC法对CYR61、VEGF-C、IL-6、cytochrome c、caspase-3和Ki-67的表达水平进行检测,并对不同分子标记物与BPH临床进展危险因素之间的相关性进行分析。利用免疫荧光双染技术检测BPH组织中CYR61和VEGF-C的同步表达和定位。结果:288例BPH标本中CYR61、VEGF-C、IL-6、cytochrome c、caspase-3和Ki-67的阳性表达例数分别为198例、221例、135例、76例、109例和102例,其阳性表达率分别为68.8%、76.7%、46.9%、26.4%、37.8%和35.4%。CYR61和VEGF-C表达与患者年龄、前列腺体积、血清PSA水平呈正相关(P＜0.05)。cytochrome c和caspase-3表达与前列腺体积呈负相关(P＜0.05)。CYR61和VEGF-C的免疫荧光双染结果证实了BPH组织中CYR61和VEGF-C的同步表达。结论:CYR61和VEGF-C的高表达对BPH的临床进展可能具有预测作用。
- CYR61 /
- VEGF-C /
- 临床进展危险因子 /
- 良性前列腺增生 /
- 组织芯片技术
Abstract: Objective: The pathogenesis and development of benign prostatic hyperplasia (BPH) have been widely studied. This study aimed to investigate the possible role of CYR61, vascular endothelial growth factor-C (VEGF-C), interleukin-6 (IL-6), cytochrome c, caspase-3 and Ki-67 in the clinical progression of BPH. Method: All tissue specimens from 288 BPH cases who underwent transurethral resection of the prostate (TURP) were processed and transferred to tissue microarrays. Patients' age, prostate volume, serum prostate specific antigen (PSA) level and international prostate symptom score (IPSS) of BPH cases were collected before surgery. The expression of CYR61, VEGF-C, IL-6, cytochrome c, caspase-3 and Ki-67 were examined by immunohistologic ABC method in BPH specimens, and possible correlation between different biomarkers and the risk factors of BPH clinical progression was also analyzed. The co-localization of CYR61 with VEGF-C protein was observed by double-label immunofluorescence. Result: The positive expression of CYR61, VEGF-C, IL-6, cytochrome c, caspase-3 and Ki-67 in BPH cases were 68.8% (198/288), 76.7% (221/288), 46.9% (135/288), 26.4% (76/288), 37.8% (109/288) and 35.4% (102/288), respectively. The expression of both CYR61 and VEGF-C were positively correlated with patients' age, prostate volume, serum PSA level (P＜0.05). Furthermore, cytochrome c and caspase-3 expression were negatively correlated with prostate volume (P＜0.05). Double-label immunoflurescence staining revealed the co-localization of CYR61 and VEGF-C in BPH tissues, especially in BPH stromal cells.Conclusion: CYR61 and VEGF-C expression may serve as biomarkers for the prediction of BPH clinical progression.
- CYR61 /
- VEGF-C /
- clinical progression risk factors /
- benign prostatic hyperplasia /
- tissue microarray technique

HTML全文

参考文献(14)

[1]	Egan K B.The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptom:prevalence and incident rates[J].Urol Clin North Am, 2016, 43 (3):289-297.
[2]	Arivazhagan J, Nandeesha H, Dorairajan L N, et al.Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia[J].Aging Male, 2017, 20 (2):115-118.
[3]	Asiedu B, Anang Y, Nyarko A, et al.The role of sex steroid hormones in benign prostatic hyperplasia[J].Aging Male, 2017, 20 (1):17-22.
[4]	Gandaqlia G, Zaffuto E, Fossati N.The role of prostatic inflammation in the development and progression of benign and malignant diseases[J].Curr Opin Urol, 2017, 27 (2):99-106.
[5]	Di Y, Zhang Y, Hui L, et al Cysteine-rich 61 RNA interference inhibits pathological angiogenesis via the phosphatidylinositol 3-kinase/AkT-vascular endothelial growth factor signal pathway in endothelial cells[J].Mol Med Rep, 2016, 14 (5):4321-4327.
[6]	Grivas N, Goussia A, Stefanou D, et al.Microvascular density and immunohistochemical expression of VEGF, VEGFR-1 and VEGFR-2 inbenign prostatic hyperplasia, high-grade prostate intraepithelial neoplasia and prostate cancer[J].Cent European J Urol, 2016, 69 (1):63-71.
[7]	Gandaglia G, Zaffuto E, Fossati N, et al.The role of prostatic inflammation in the development and progression of benign and malignant diseases[J].Curr Opin Urol, 2017, 27 (2):99-106.
[8]	Ummanni R, Lehnigk U, Zimmermann U, et al.Immunohistochemical expression of caspase-1 and-9, uncleaved caspase-3 and-6, cleaved caspase-3 and-6 as well as Bcl-2 in benign epithelium and cancer of the prostate[J].Exp Ther Med, 2010, 1 (1):47-52.
[9]	Zhong W D, Peng J, He H C, et al.Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia[J].Clin Invest Med, 2008, 31 (1):E8-E15.
[10]	Elena-Real C A, Diaz-Quintana A, Gonzalez-Arzola K, et al.Cytochrome c speed up caspase cascade activation by blocking 14-3-3-dependent Apaf-1 inhibition[J].Cell Death Dis, 2018, 9 (3):365.
[11]	郑曙东, 李三山, 梁雪松, 等.经尿道等离子双极电切术治疗体积大于50 ml BPH临床体会[J].临床泌尿外科杂志, 2015, 30 (8):751-752.
[12]	Kostis G, Ioannis L, Helen K, et al.The expression of vascular endothelial growth factor-C correlates with lymphatic microvessel density and lymph node metastasis in prostate carcinoma:An inmunohischemical study[J].Urol Ann, 2014, 6 (3):224-230.
[13]	Minutoli L, Rinaldi M, Marini H, et al.Apoptotic pathways linked to endocrine system as potential therapeutic targets for benign prostatic hyperplasia[J].Int J Mol Sci, 2016.
[14]	Kim J H, Han I H, Kim Y S, et al.Proliferation of prostate epithelial induced by IL-6 from stroma reacted with T vaginalis[J].Parasite Immunol, 2018, 4 (6):e12531-e12531.